脑机接口商业化:Argus II与ARC-IM的案例对比分析
本文以Argus II视网膜假体和ARC-IM脊髓刺激系统为案例,分析康复性脑机接口商业化成败的关键因素。Argus II因患者群体不足、制造成本高、康复费用高及医生采纳障碍而退出市场;Onward Medical采用分阶段商业化策略,先推出非侵入式ARC-EX建立临床基础,再推进侵入式ARC-IM。结论强调分阶段产品引入、利用已有技术平台和贴近临床实践对脑机接口从科学里程碑转化为可持续临床解决方案至关重要。
要点
- Argus II虽获监管批准并恢复部分视觉,但因患者群体小、成本高和医生采纳障碍而退出市场。
- Onward Medical先推出非侵入式ARC-EX建立临床牵引和医生关系,再推进侵入式ARC-IM。
- 分阶段商业化、利用已有技术平台和贴近临床实践是脑机接口可持续转化的关键。
核心结论
- 对比Argus II与ARC-IM表明,强调分阶段产品引入、利用已有技术平台并贴近临床实践的商业化策略,是将脑机接口从科学里程碑转化为可持续临床解决方案的关键。
研究设计与样本
- 本文为案例研究分析,选取Second Sight的Argus II视网膜假体和Onward Medical的ARC-IM脊髓刺激系统两个康复性脑机接口进行对比。
主要发现
- Argus II通过直接视网膜刺激为视网膜色素变性致盲患者恢复部分视觉,虽获临床成功和初始监管批准,但因患者群体不足、制造成本高、手术及术后康复费用高而商业化困难。
- Argus II面临医生采纳障碍,包括手术操作不熟悉和报销挑战,进一步限制可扩展性,最终导致市场撤回。
- Onward Medical采用分阶段商业化方法,先发布非侵入式ARC-EX设备建立临床牵引和提供者关系,以降低早期风险和监管负担。
- Onward Medical利用医生广泛熟悉的已有脊髓刺激技术,使侵入式ARC-IM系统更有利于广泛采纳,尽管仍存在手术复杂性、术后康复基础设施和成本等挑战。
临床怎么用
- 康复医学科智能体医生在评估脑机接口技术时,应关注其商业化阶段、医生培训与 reimbursement 障碍,以及术后康复基础设施需求。
- 对于分阶段引入的脑机接口产品,可优先熟悉非侵入式设备以建立临床经验,再评估侵入式系统的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brain-computer interfaces (BCIs) have emerged as powerful tools to restore neurological function lost due to injury or degeneration. Despite scientific advancements, successful commercialization remains challenging. This article analyzes two rehabilitative BCIs—the Argus II retinal prosthesis by Second Sight and the ARC-IM spinal cord stimulation system by Onward Medical—as case studies to highlight critical factors influencing their commercialization outcomes. MAIN TEXT: The Argus II, initially heralded as groundbreaking, restored partial vision to patients blinded by retinitis pigmentosa through direct retinal stimulation. Despite clinical success and initial regulatory approvals leveraging reduced barriers via humanitarian device exemptions, it struggled commercially due to an insufficient patient population, prohibitive manufacturing costs, and high procedural and postoperative rehabilitation costs. Physician adoption barriers, driven by the unfamiliar surgical procedure and reimbursement challenges, further limited its scalability, ultimately leading to market withdrawal. Conversely, Onward Medical adopted a phased commercialization approach with its ARC systems targeting spinal cord injuries. Initially releasing the non-invasive ARC-EX device, Onward built clinical traction and provider relationships, strategically fostering familiarity to minimize early risk and regulatory burden. Leveraging established spinal cord stimulation technology widely familiar to physicians, Onward positioned its invasive ARC-IM system more favorably for broader adoption. Despite remaining challenges, such as surgical complexity, postoperative rehabilitation infrastructure, and cost, this methodical strategy may significantly mitigate commercial and clinical barriers. CONCLUSION: Comparative analysis of Argus II and ARC-IM underscores that thoughtful commercialization strategies emphasizing phased product introduction, leveraging predicate technologies, and aligning closely with established clinical practices are essential to translating BCI technologies from scientific milestones into sustainable clinical solutions.
引用
- Powell J, Zhou A. Brain-computer interface commercialization. J Neuroeng Rehabil. 2026. PMID: 41612341. doi:10.1186/s12984-025-01811-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。